FIMBRION THERAPEUTICS INC has a total of 13 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, China and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are RFS PHARMA LLC, ALIOS BIOPHARMA INC and NOVIRIO PHARMACEUTICALS LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 3 | |
#2 | China | 2 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Australia | 1 | |
#6 | Brazil | 1 | |
#7 | Canada | 1 | |
#8 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Sugars | |
#4 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Mydock-Mcgrane Laurel | 11 |
#2 | Janetka James W | 11 |
#3 | Mydock Mcgrane Laurel | 1 |
#4 | Janetka James | 1 |
#5 | Laurel Mydock-Mcgrane | 1 |
#6 | James W Janetka | 1 |
Publication | Filing date | Title |
---|---|---|
EP3432892A1 | Mannose-derived antagonists of fimh useful for treating disease | |
EP3426260A1 | C-glycoside compounds useful for treating disease |